Diagnosed with cancer

after taking Zantac?


Zantac has been linked to the human carcinogen  NDMA.

The FDA called for all Zantac to be pulled from the shelves. 

Get a Free Consultation

This field is for validation purposes and should be left unchanged.

Zantac Lawsuits: Carcinogen Prompts Recall


ALERT: April 1, 2020 – “The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine (Zantac) drugs from the market immediately.”


Since the 1980s, ranitidine (brand name: Zantac) has been associated with NDMA. While Zantac is not contaminated with NDMA, it contains nitrite (N) and dimethylamine (DMA). Combined, they form the carcinogen NDMA.

The Food and Drug Administration (FDA) was notified in June of 2019 that routine testing done in Valisure’s labs had linked Zantac to N-nitrosodimethylamine (NDMA).  FDA’s own testing found unacceptable levels of NDMA in Zantac.


“The results [of several case–control studies and one cohort study] are supportive of the assumption that NDMA consumption is positively associated with either gastric or colorectal cancer.” (World Health Organization)


On April 1, 2020, the FDA issued a recall on Zantac. In addition to NDMA concerns, “the agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures may result in consumer exposure to unacceptable levels of this impurity.”


If you have been diagnosed with cancer after taking Zantac regularly, please contact us immediately by calling 504-523-2434 or filling out an online Contact Form for a FREE Consultation.

Possible side-effects include:

Bladder cancer

Colon and rectal cancer

Esophageal cancer

Intestinal cancer

Kidney cancer

Liver cancer

Lung cancer (non-smokers)

and more

Cancer diagnosis after taking Zantac?

Why Choose Peiffer Wolf?

We handle cases that change lives.


Peiffer Wolf is committed to making sure that the companies that release harmful drugs or medical devices onto the market are held accountable for their wrongful conduct. Our firm’s Pharmaceutical and Medical Devices practice is led by Attorney Daniel Carr, who has represented thousands of clients from across the United States in cases related to pharmaceutical products and medical devices, including litigations involving Essure, Truvada, Low-T, Xarelto, Pradaxa, ASR hip implants, TVM, Actos, Invokana, Onglyza, and others.


With offices in New York, California, Louisiana, Missouri and Ohio, we have the size, experience, resources and leverage to prosecute complex cases against major corporations nationwide. We attribute our history of success to the sophistication, experience, and professionalism of our widely respected lawyers.

Cancer diagnosis after taking Zantac or Ranitidine?